User profiles for Heng-Keang Lim
 | Heng-Keang LimScientific Director and Fellow, Janssen R & D Verified email at its.jnj.com Cited by 3466 |
Reproducing human and cross-species drug toxicities using a Liver-Chip
Nonclinical rodent and nonrodent toxicity models used to support clinical trials of candidate
drugs may produce discordant results or fail to predict complications in humans, contributing …
drugs may produce discordant results or fail to predict complications in humans, contributing …
The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of …
Time-dependent inhibition (TDI) of cytochrome P450 (P450) enzymes caused by new molecular
entities (NMEs) is of concern because such compounds can be responsible for clinically …
entities (NMEs) is of concern because such compounds can be responsible for clinically …
A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates …
EA Dierks, KR Stams, HK Lim, G Cornelius… - Drug Metabolism and …, 2001 - ASPET
A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing
cytochrome P450s (CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2C19, CYP2A6, and …
cytochrome P450s (CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2C19, CYP2A6, and …
Fasiglifam (TAK-875): mechanistic investigation and retrospective identification of hazards for drug induced liver injury
TAK-875, a GPR40 agonist, was withdrawn from Phase III clinical trials due to drug-induced
liver injury (DILI). Mechanistic studies were conducted to identify potential DILI hazards (…
liver injury (DILI). Mechanistic studies were conducted to identify potential DILI hazards (…
Metabolite identification by data‐dependent accurate mass spectrometric analysis at resolving power of 60 000 in external calibration mode using an LTQ/Orbitrap
HK Lim, J Chen, C Sensenhauser… - … Journal Devoted to …, 2007 - Wiley Online Library
Performance evaluation of accurate mass measurement by the LTQ/Orbitrap, at a resolving
power of 60 000 and in external calibration mode, indicated that the Orbitrap is capable of …
power of 60 000 and in external calibration mode, indicated that the Orbitrap is capable of …
Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes
A strategy is proposed to profile compounds for mechanism-based inactivation of CYP3A4,
CYP2C19, CYP2C9, CYP2D6, and CYP1A2 based on an apparent partition ratio screen. …
CYP2C19, CYP2C9, CYP2D6, and CYP1A2 based on an apparent partition ratio screen. …
Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans
…, MF Kelley, D Devineni, MD Johnson, HK Lim - Drug Metabolism and …, 2014 - ASPET
Canagliflozin is an oral antihyperglycemic agent used for the treatment of type 2 diabetes
mellitus. It blocks the reabsorption of glucose in the proximal renal tubule by inhibiting the …
mellitus. It blocks the reabsorption of glucose in the proximal renal tubule by inhibiting the …
Recognition of cell‐wall peptide ligands by vancomycin group antibiotics: Studies using ion spray mass spectrometry
Non‐covalent binding of antibiotics to their target ligands represents a form of molecular
recognition which is of considerable contemporary interest in bioorganic and bioanalytical …
recognition which is of considerable contemporary interest in bioorganic and bioanalytical …
The effect of a high‐fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin)
JJ Zimmerman, GM Ferron, HK Lim… - The Journal of Clinical …, 1999 - Wiley Online Library
The bioavailability of an oral nonaqueous solution of sirolimus was compared under fasting
conditions and after a high‐fat meal in a randomized, two‐way crossover pharmacokinetic …
conditions and after a high‐fat meal in a randomized, two‐way crossover pharmacokinetic …
Design and Characterization of Optimized Adenosine A2A/A1 Receptor Antagonists for the Treatment of Parkinson's Disease
…, L Lampron, L Westover, HK Lim… - Journal of medicinal …, 2012 - ACS Publications
The design and characterization of two, dual adenosine A 2A /A 1 receptor antagonists in
several animal models of Parkinson's disease is described. Compound 1 was previously …
several animal models of Parkinson's disease is described. Compound 1 was previously …